AnBogen Therapeutics, Inc. is a precision oncology company that develops therapies for cancer treatment. AnBogen leverages diverse roots, scientific knowledge, and expertise in drug discovery and development to create therapies aimed at transforming cancer treatment.

AnBogen Therapeutics, Inc.

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs.

Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development. 


AnBogen Therapeutics

Anbogen Therapeutics is pleased to announce the successful closing of a USD 7.3M oversubscribed A+ round financing, bringing our total Series A funding to USD 19.8M. This funding will advance the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer.

Read the complete news release here: https://reurl.cc/MOEGQ3
#SeriesA+ #AnbogenTherapeutics #ABT301 #immunecheckpointinhibitors

Delighted to announce the successful completion of Anbogen Therapeutics' Series A, with USD 12.5 million raised. Gratitude to our investors for their support as we advance in developing precision anti-cancer drugs. Read the complete news release here: https://lnkd.in/gpacKFWF
#SeriesA #Biotech #Innovation #AnbogenTherapeutics

Happy New Year from all of us at Anbogen! As we enter 2024, we're not only celebrating the possibilities ahead but also eagerly anticipating sharing more of our precision drug development progress with you this year. Wishing everyone a year filled with success, health, and exciting discoveries!
#ABT-101 #ABT-301 #ABT-202

Metric
Company Name	AnBogen Therapeutics, Inc.
Symbol
MSH ID	COM:ANBOGEN
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	16
Website	anbogen.com
LinkedIn	anbogen-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ANBOGEN

AnBogen Therapeutics, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue